Neogenomics

Test volumes, revenues per test and costs per test improved during the quarter, company executives said.

The index fell more than 11 percent in December, underperforming the Dow and the Nasdaq, but performing on par with the Nasdaq Biotechnology Index.

Qiagen will provide IUO tests for NeoGenomics to verify, set up, and run in clinical trials and in anticipation of regulatory approval.

After six straight months of gains, the index saw a sharp drop in October that even positive earnings news could not stave off.

The company saw double-digit volume growth in its clinical services division in the quarter, coupled with increased revenue per test.

NeoGenomics will pay $125 million in cash and distribute 1 million shares of its stock to Genoptix, a clinical oncology lab, as part of the deal.

The company will use its NeoType Discovery Panel for the trial. The panel assesses 320 cancer-related genes in solid tumors, hematologic malignancies, and advanced sarcomas.

Premier is a healthcare group purchasing organization representing about 4,000 hospitals and 165,000 other providers throughout the US.

Proceeds from the offering, expected to close on or about Aug. 14, could be used to fund acquisitions, to repay existing debts, or for working capital.